Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer

Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer Oncol Ther (2016) 4:103–116 DOI 10.1007/s40487-016-0020-4 ORIGINAL RESEARCH Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer . . . Lourens T. Bloem Richard De Abreu Lourenc ¸o Melvin Chin Brett Ly Marion Haas Received: March 4, 2016 / Published online: May 11, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com in the Sydney metropolitan area, Australia were ABSTRACT identified using the hospital’s database Introduction: To investigate the factors that MOSAIQ . The electronic medical record of affect the choice of 5-fluorouracil (5-FU) or its each patient was manually reviewed to extract oral alternative, capecitabine, as first-line factors potentially affecting treatment choice. treatment in patients with colorectal cancer Logistic regression was used to assess which (CRC). patient and/or treatment factors could explain Methods: Patients treated with 5-FU or the choice between 5-FU or capecitabine. Where capecitabine for CRC between January 1, 2011 it was available in the medical correspondence, and December 31, 2013 in a teaching hospital the explicit reason for the choice made was extracted. Enhanced content To view enhanced content for this Results: 170 CRC patients were included; 119 article go to www.medengine.com/Redeem/ 05C4F060100E857A. on 5-FU, and 51 on capecitabine. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer

Download PDF
14 pages

Loading next page...
 
/lp/springer-journals/factors-impacting-treatment-choice-in-the-first-line-treatment-of-vjYDbkdwu9
Publisher
Springer Journals
Copyright
Copyright © 2016 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2366-1089
DOI
10.1007/s40487-016-0020-4
Publisher site
See Article on Publisher Site

Abstract

Oncol Ther (2016) 4:103–116 DOI 10.1007/s40487-016-0020-4 ORIGINAL RESEARCH Factors Impacting Treatment Choice in the First-Line Treatment of Colorectal Cancer . . . Lourens T. Bloem Richard De Abreu Lourenc ¸o Melvin Chin Brett Ly Marion Haas Received: March 4, 2016 / Published online: May 11, 2016 The Author(s) 2016. This article is published with open access at Springerlink.com in the Sydney metropolitan area, Australia were ABSTRACT identified using the hospital’s database Introduction: To investigate the factors that MOSAIQ . The electronic medical record of affect the choice of 5-fluorouracil (5-FU) or its each patient was manually reviewed to extract oral alternative, capecitabine, as first-line factors potentially affecting treatment choice. treatment in patients with colorectal cancer Logistic regression was used to assess which (CRC). patient and/or treatment factors could explain Methods: Patients treated with 5-FU or the choice between 5-FU or capecitabine. Where capecitabine for CRC between January 1, 2011 it was available in the medical correspondence, and December 31, 2013 in a teaching hospital the explicit reason for the choice made was extracted. Enhanced content To view enhanced content for this Results: 170 CRC patients were included; 119 article go to www.medengine.com/Redeem/ 05C4F060100E857A. on 5-FU, and 51 on capecitabine.

Journal

Oncology and Therapy – Springer Journals

Published: May 11, 2016

References

  • Treatment decisions after diagnosis of metastatic colorectal cancer
    Cartwright, TH
  • Current opinion on optimal treatment for colorectal cancer
    Price, TJ; Segelov, E; Burge, M; Haller, DG; Ackland, SP; Tebbutt, NC
  • Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy
    Twelves, C; Scheithauer, W; McKendrick, J; Seitz, J-F; Hazel, G; Wong, A
  • Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma
    Twelves, C; Boyer, M; Findlay, M; Cassidy, J; Weitzel, C; Barker, C
  • Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes’ C colon cancer: the X-ACT trial
    Cassidy, J; Douillard, JY; Twelves, C; McKendrick, JJ; Scheithauer, W; Bustova, I
  • Cost consequences of adjuvant capecitabine, Mayo Clinic and de Gramont regimens for stage III colon cancer in the French setting
    Douillard, JY; Tilleul, P; Ychou, M; Dufour, P; Perrocheau, G; Seitz, JF
  • Medical resource use and cost of different first-line treatments for metastatic colorectal cancer in Brazil
    Caponero, R; Albuquerque Ribeiro, R; Santos, E; Cirrincione, A; Saggia, M
  • Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes’ C colon cancer: economic evaluation in an Italian NHS setting
    Costanzo, F; Ravasio, R; Sobrero, A; Bertetto, O; Vinante, O; Luppi, G
  • Cost-analysis of XELOX and FOLFOX4 for treatment of colorectal cancer to assist decision-making on reimbursement
    Tse, VC; Ng, WT; Lee, V; Lee, AWM; Chua, DTT; Chau, J
  • Cost identification of Nordic FLIRI, Nordic FLOX, XELIRI and XELOX in first-line treatment of advanced colorectal cancer in Sweden—A clinical practice model approach
    Pettersson, K; Carlsson, G; Holmberg, C; Sporrong, SK
  • Real-world resource use and costs of adjuvant treatment for stage III colon cancer
    Gils, CW; Groot, S; Tan, SS; Redekop, WK; Koopman, M; Punt, CJ
  • Cost-benefit analysis of capecitabine versus 5-flourouracil/leucovorin in the treatment of colorectal cancer in the Netherlands
    Jansman, FGA; Postma, MJ; Hartskamp, D; Willemse, PHB; Brouwers, JRBJ
  • A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer
    Twelves, C; Gollins, S; Grieve, R; Samuel, L
  • Oral treatment of metastatic breast cancer with capecitabine: what influences the decision-making process?
    Gornas, M; Szczylik, C
  • Patient preferences for oral versus intravenous palliative chemotherapy
    Liu, G; Franssen, E; Fitch, MI; Warner, E
  • Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin: a randomised crossover trial in advanced colorectal cancer
    Borner, MM; Schoffski, P; Wit, R; Caponigro, F; Comella, G; Sulkes, A
  • Randomized crossover trial of intravenous 5-FU versus oral UFT both modulated by leucovorin: a one-centre experience
    Rocha Lima, AP; Del Giglio, A
  • Patient preference for oral or intravenous chemotherapy: a randomised cross-over trial comparing capecitabine and nordic fluorouracil/leucovorin in patients with colorectal cancer
    Pfeiffer, P; Mortensen, JP; Bjerregaard, B; Eckhoff, L; Schonnemann, K; Sandberg, E
  • A randomised crossover trial of chemotherapy in the home: patient preferences and cost analysis
    Rischin, D; White, MA; Matthews, JP; Toner, GC; Watty, K; Sulkowski, AJ
  • Home care–a safe and attractive alternative to inpatient administration of intensive chemotherapies
    Luthi, F; Fucina, N; Divorne, N; Santos-Eggimann, B; Currat-Zweifel, C; Rollier, P
  • Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial
    Borras, JM; Sanchez-Hernandez, A; Navarro, M; Martinez, M; Mendez, E; Ponton, JLL
  • Age and adjuvant chemotherapy use after surgery for stage III colon cancer
    Schrag, D; Cramer, LD; Bach, PB; Begg, CB
  • Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer
    Potosky, AL; Harlan, LC; Kaplan, RS; Johnson, KA; Lynch, CF
  • Survival associated with 5-fluorouracil-based adjuvant chemotherapy among elderly patients with node-positive colon cancer
    Sundararajan, V; Mitra, N; Jacobson, JS; Grann, VR; Heitjan, DF; Neugut, AI
  • Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort
    Ayanian, JZ; Zaslavsky, AM; Fuchs, CS; Guadagnoli, E; Creech, CM; Cress, RD
  • Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation
    Jessup, J; Stewart, A; Greene, FL; Minsky, BD
  • Patterns of care for adjuvant therapy in a random population-based sample of patients diagnosed with colorectal cancer
    Cronin, DP; Harlan, LC; Potosky, AL; Clegg, LX; Stevens, JL; Mooney, MM
  • Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer
    Kahn, KL; Adams, JL; Weeks, JC
  • Assessing compliance with National Comprehensive Cancer Network guidelines for elderly patients with stage III colon cancer: the fox chase cancer center partners’ initiative
    O’Grady, MA; Slater, E; Sigurdson, ER; Meropol, NJ; Weinstein, A; Lusch, CJ
  • Adherence to stage-specific treatment guidelines for patients with colon cancer
    Chagpar, R; Xing, Y; Chiang, Y-J; Feig, BW; Chang, GJ; You, YN
  • Taking responsibility for cancer treatment
    Deadman, JM; Leinster, SJ; Owens, RG; Dewey, ME; Slade, PD
  • Information needs and decisional preferences in women with breast cancer
    Degner, LF; Kristjanson, LJ; Bowman, D
  • Patient preferences versus physician perceptions of treatment decisions in cancer care
    Bruera, E; Sweeney, C; Calder, K; Palmer, L; Benisch-Tolley, S
  • Preferences of colorectal cancer patients for treatment and decision-making: a systematic literature review
    Damm, K; Vogel, A; Prenzler, A
  • Comparative effectiveness of chemotherapy in elderly patients with metastatic colorectal cancer
    Satram-Hoang, S; Lee, L; Yu, S; Guduru, SR; Gunuganti, AR; Reyes, C
  • Comparative effectiveness of 5-fluorouracil with and without oxaliplatin in the treatment of colorectal cancer in clinical practice
    Healey, E; Stillfried, GE; Eckermann, S; Dawber, JP; Clingan, PR; Ranson, M